CBER Site Map

About CBER

  • Action Plans
  • Biologics Centennial
  • Contact Information
  • Employment
  • FAQs
  • General Information / Reports
  • Mission Statement
  • Organization
  • Impact of Severe Weather Conditions
  • FDA Strategic Plan
Contact CBER

  • Email
  • Phone
  • Mail
Jobs at CBER

Subscribe to CBER

Privacy Statement

Web Accessibility

Products

  • Product Approval Information
  • Product Labeling
  • Product / Manufacturer Lists
  • Adverse Event & Biological Product Deviation Reporting
  • Blood Establishment Computer Software
  • Compliance / Surveillance
  • Donor Screening / HIV
  • Export Certification
  • Fast Track Performance Reports
  • Product Deviation Reports
  • Product Shortages
  • Postmarket Commitments
  • Recalls / Withdrawals / Field Corrections
  • Safety Information
  • User Fee Billable Products
  • Violative Advertising & Promotional Labeling Letters
      - Other Compliance Actions
  • Transfer of Therapeutic Products to CDER

Industry

  • Action Plans
  • Adverse Event Reporting
  • Code of Federal Regulations - Biologics Related
  • Clinical Investigator Information
  • Clinical Investigator Inspection List
  • Combination Products
  • Compliance / Surveillance
  • Counterfeit Initiative
  • Device Application Submission
  • Electronic Submissions
  • Export Certification
  • Fast Track Performance Reports
  • FAQs
  • FDAMA (FDA Modernization Act)
  • Guidances
  • How to Submit an IND (Investigational New Drug Application)
  • Electronic IND Demo
  • MDUFMA (Medical Device User Fee & Modernization Act)
  • Notice of Initiation of Disqualification Proceedings and Opportunity to Explain (NIDPOE) Letters
  • PDMA (Prescription Drug Marketing Act)
  • PDUFA (Prescription Drug User Fee Act)
  • PHS Act - Licensing Biological Products
  • User Fee Billable Products
  • Product Shortages
  • Postmarket Commitments
  • Publications / Reading Room
  • Small Business Information
  • CBER SOPPS (Standard Operating Procedures and Policies)

Consumer / Healthcare Information

  • Adverse Event Reporting
      - Biological Product Deviation Reporting
      - MedWatch
      - Transfusion / Donation Related Fatalities
      - Vaccine Adverse Event Reporting System
  • All About Vaccines for Kids
  • Clinical Investigator Information
  • Compliance / Surveillance
  • Counterfeit Initiative
  • Countering Bioterrorism
  • FDA Patient Safety News
  • Frequently Asked Questions
      - General
      - Blood
      - Vaccines
  • Healthcare Letters
  • Information Sheets
  • Keeping Blood Transfusions Safe
  • NIH Clinical Trials Database
  • NLM MEDLINEplus Health Information
  • Product Approvals
  • Product Labeling
  • Product Shortages
  • Recalls / Withdrawals / Field Corrections
  • Safety Information
  • Vaccines Provide Effective Protection
  • Violative Advertising & Promotional Labeling Letters
  • Warning Letters
      - Other Compliance Actions
  • FDA Consumer / Healthcare Information
  • FDA Consumer Magazine

Reading Room (EFOIA)

  • Approval Information
  • Blood Memos
  • Code of Federal Regulations - Biologics Related
  • Compliance Programs
  • Compliance / Surveillance
  • FDA Modernization Act (FDAMA)
  • Guidances
  • Healthcare Letters
  • Information Sheets
  • Meeting Minutes
  • Medical Device User Fee & Modernization Act (MDUFMA)
  • Notice of Initiation of Disqualification Proceedings and Opportunity to Explain (NIDPOE) Letters
  • Postmarket Commitments
  • Prescription Drug User Fee Act (PDUFA)
  • Presentations / Summaries
  • Product Shortages
  • Recalls / Withdrawals / Field Corrections
  • Rules
  • Safety Information
  • Talk Papers
  • Transfer of Therapeutic Products to CDER
  • Violative Advertising & Promotional Labeling Letters
  • Warning Letters
      - Other Compliance Actions
  • Additional Documents Available From FDA
  • Related Publications

Meetings and Workshops

  • Advisory Committees
  • Clinical Hold / Refusal to File Meetings
  • FDAMA - Stakeholder
  • Minutes / Transcripts
  • Presentations / Summaries
  • Workshops & Conferences
Blood

  • Advisory Committees
      - Blood Products
      - Transmissible Spongiform Encephalopathies
      - HHS Blood Safety
  • Albumin Safety
  • Blood Action Plan
  • Blood Establishment Computer Software
  • Blood Establishment Registration
  • Blood Establishment Registration Public Query
  • Bovine Spongiform Encephalopathy (BSE)
  • Compliance Programs
  • DIC following Rho(D) IGIV Administration
  • Donor Screening / HIV
  • Exceptions & Alternative Procedures Under 21CFR640.120
  • Frequently Asked Questions
  • Hemochromatosis Variances
  • Keeping Blood Transfusions Safe
  • Mercury in Plasma-Derived Products
  • NIH Human Embryonic Stem Cell Registry
  • Publications (Guidances, Rules, Info Sheets, Memoranda)
  • SARS
  • Transfusion Related Acute Lung Injury (TRALI)
  • Varicella Zoster Immune Globulin (VZIG)
  • West Nile Virus / Blood Safety

Vaccines

  • Adverse Event Reporting System (VAERS)
  • Advisory Committee
      - Vaccines & Related Biological Products
  • Anthrax
  • Approval Process
  • Bovine Spongiform Encephalopathy (BSE)
  • Frequently Asked Questions
  • Flu (Influenza) Vaccine
  • Licensed / Distributed Vaccines
  • Publications / Transcripts
  • Smallpox
  • Thimerosal
  • Vaccines for Kids
  • Vaccines Provide Effective Protection
  • Vaccines and Autism

Cellular & Gene Therapy

  • Advisory Committee
      - Cellular, Tissue & Gene Therapies
  • Cellular Therapy: Potential Treatment for Heart Disease
  • Cloning Technology
  • Gene Therapy Patient Tracking System
  • Human Gene Therapy and the Role of the FDA
  • New Human Gene Transfer Research Data System
  • Publications
  • Recombinant DNA and Gene Transfer, Office of Biotechnology Activities, NIH
  • Type I Diabetes / Pancreatic Islet Transplantation
  • Warning Letters

Tissue

  • Adverse Reaction Reporting
  • Advisory Committee
      - Cellular, Tissue & Gene Therapies
  • Establishment Inspection Related Documents
  • Exemptions and Alternative Procedures Under 21 CFR Part 1271.155
  • HCT / P Deviation Reporting
  • Meeting Information
  • NIH Human Embryonic Stem Cell Registry
  • Nucleic Acid Testing of Cadaveric Donors
  • Publications
  • Tissue Action Plan
  • Tissue Reference Group
  • Tissue Banks: Dangers of Tainted Tissue
  • Tissue Registration
  • Tissue Registration Public Query
  • Tissue Related Product Approvals
  • Xenotransplantation Action Plan

Devices

  • Device Action Plan
  • Devices Regulated by CBER
  • Medical Device User Fee & Modernization Act (MDUFMA)
  • Publications
  • Application Submission Information
  • Blood Establishment Computer Software
  • Donor Screening / HIV

Allergenics

  • Allergenic Products Advisory Committee
  • Publications

Research

  • Investigators
  • Research Projects Search
  • Research Opportunities
  • FDA-NCI Clinical Proteomics Program

Countering Bioterrorism

  • Anthrax
  • Smallpox
  • Frequently Asked Questions
  • Bioterrorism Act of 2002
  • Project BioShield Act of 2004
  • Security Resource Sheet
  • FDA, HHS, CDC Bioterrorism Information
 
Updated: August 1, 2008